Dinaciclib is an inhibitor of CDK 1, 2, 5, 9, and 12 that impairs the transcription of DNA-repair genes including RAD51. In the last years, dinaciclib has demonstrated a potential antitumor activity for the treatment of solid cancers including BC (NCT01676753; NCT00732810; NCT01434316). This evidence concerns the gene RAD51 and breast cancer.